VivoSeq
Other

Intellectual Disability

6

Pipeline Programs↗

5

Active Trials↗

5

Companies Involved↗

Intellectual disability is an early-stage landscape with 6 programs across 5 companies. The most active players are Merz Pharmaceuticals GmbH, EMD Serono, Jazz Pharmaceuticals. 2 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Merz Pharmaceuticals GmbH

1 program

Phase 3EMD Serono logo

EMD Serono

1 program

ApprovedJazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

ApprovedGSK logo

GSK

1 program

PreclinicalAbbVie logo

AbbVie

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

13

clinical trials

Completed7 · 54%
Recruiting3 · 23%
Active, not recruiting2 · 15%
Unknown status1 · 8%

Clinical Trials

Trial Activity

13 trials

Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
Recruiting·CCentre for Addiction and Mental Health·Phase 4·NCT05744479·100 enrolled
Characterization of the Nociception Phenotype in Individuals With Intellectual Disability
Recruiting·National Institutes of Health Clinical Center (CC)·Preclinical·NCT05473429·215 enrolled
Investigations of Individuals With MEHMO Syndrome or eIF2-Pathway Related Conditions
Recruiting·Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·N/A·NCT06019182·150 enrolled
Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
Active, not recruiting·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 2·NCT04529226·75 enrolled
Improving the Health of Parents and Their Adolescent and Transition-age Youth With Intellectual and Developmental Disabilities
Active, not recruiting·UUniversity of North Carolina, Chapel Hill·Preclinical·NCT05986305·406 enrolled
Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
Completed·HHospices Civils de Lyon·N/A·NCT02451761·55 enrolled
Comparison of Immediate vs Gradual Switch to Divalproex in Adults With Intellectual Disability
Completed·UUniversity of Kansas·N/A·NCT00347152·18 enrolled
Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
Completed·MMurdoch Childrens Research Institute·Phase 2·NCT04821856·132 enrolled
Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
Completed·MMerz Pharmaceuticals GmbH·Phase 3·NCT02270736·256 enrolled
Contribution of High Throughput RNA Sequencing Combined With Sequencing of Whole Genomes in the Diagnosis of Intellectual Disability
Completed·—·N/A·NCT03857997·62 enrolled
Comparison of Sensory-Adapted (SADE) and Regular Dental Environments (RDE) in Patients With Mild Intellectual Disability and Moderate Dental Anxiety
Completed·Oasi Research Institute-IRCCS·Preclinical·NCT07413016·200 enrolled
Etude Pilote Des différentes stratégies de séquençage Haut débit du génome Pour le Diagnostic génétique Des Patients Atteints de déficience Intellectuelle
Completed·IInstitut National de la Santé Et de la Recherche Médicale, France·Preclinical·NCT04154891·3,825 enrolled
Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity
Unknown status·UUniversity Hospital, Toulouse·N/A·NCT04768803·300 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)